Diagnosis of Amebic Liver Abscess and Amebic Colitis by Detection of *Entamoeba histolytica* DNA in Blood, Urine, and Saliva by a Real-Time PCR Assay


*International Centre For Diarrhoeal Disease Research, Bangladesh, Dhaka-1000, Bangladesh; Rajshahi Medical College, Rajshahi, Bangladesh; Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; and Division of Infectious Disease and International Health, University of Virginia Health System, Charlottesville, Virginia*

The noninvasive diagnosis of amebic liver abscess is challenging, as most patients at the time of diagnosis do not have a concurrent intestinal infection with *Entamoeba histolytica*. Fecal testing for *E. histolytica* parasite antigen or DNA is negative in most patients. A real-time PCR assay was evaluated for detection of *E. histolytica* DNA in blood, urine, and saliva samples from amebic liver abscess as well as amebic colitis patients in Bangladesh. A total of 98 amebic liver abscess and 28 amebic colitis patients and 43 control subjects were examined. The real-time PCR assay detected *E. histolytica* DNA in 49%, 77%, and 69% of blood, urine, and saliva samples from the amebic liver abscess patients. For amebic colitis the sensitivity of the real-time PCR assay for detection of *E. histolytica* DNA in blood, urine, and saliva was 36%, 61%, and 64%, respectively. All blood, urine, and saliva samples from control subjects were negative by the real-time PCR assay for *E. histolytica* DNA. When the real-time PCR assay results of the urine and saliva specimens were taken together (positive either in urine or saliva), the real-time PCR assay was 97% and 89% sensitive for detection of *E. histolytica* DNA in liver abscess and intestinal infection, respectively. We conclude that the detection of *E. histolytica* DNA in saliva and urine could be used as a diagnostic tool for amebic liver abscess.

*Entamoeba histolytica* is a protozoan parasite that causes amebic diarrhea, colitis, and amebic liver abscess (ALA), mostly in developing countries (5, 7, 22, 25). Eighty percent of infected individuals remain asymptomatic carriers, while the other 20% develop clinically overt disease (7, 9, 22, 25). About 50 million symptomatic cases of amebiasis occur worldwide each year, resulting in 40,000 to 100,000 deaths annually (25). Mortality from amebiasis is mainly due to extra-amebic colitis, of which ALA is the most common.

It is difficult to differentiate ALA from pyogenic liver abscess or other space-occupying lesions of the liver. Imaging techniques such as ultrasound, computed tomography, and magnetic resonance have excellent sensitivities for the detection of liver abscesses arising from any cause, but there are no findings specific for ALA (13). Further complicating the diagnosis is the fact that most patients with an ALA do not have coexistent intestinal infection with *E. histolytica* (11). Therefore, detection of *E. histolytica* antigen or DNA in stool samples is not very helpful for the diagnosis of ALA (1, 6, 8, 12).

The current means for diagnosis of ALA is the detection of antiamebic antibody by serological tests combined with aspiration of the abscess. The presence of serum antibodies against *E. histolytica* and the absence of bacteria in the abscess fluid are consistent with an ALA. A drawback of serologic tests is that the serum antibody levels in people from areas of endemicity remain positive for years after infection with *E. histolytica* (3, 16, 23). Therefore, antiamebic antibodies in the serum may be due to amebiasis in the past, limiting their specificity for the diagnosis of ALA. A further limitation to the current approach to ALA diagnosis is that collection of liver abscess pus is an invasive procedure that requires technical expertise and can be done only in specialized hospitals.

Several groups have reported the detection of *E. histolytica* DNA in liver abscess pus, stool, and other clinical samples by PCR (14, 15, 18, 19, 21, 24, 26). A real-time PCR assay has also been used for detection of *E. histolytica* DNA in stool and liver abscess pus specimens (2, 10, 20). Real-time PCR has never been used for detection of *E. histolytica* DNA in urine, saliva, and blood specimens of ALA patients. In this study, we evaluated a real-time PCR assay to detect *E. histolytica* DNA in blood, urine, and saliva samples of amebic liver abscess and colitis patients in Bangladesh.

**MATERIALS AND METHODS**

**Patients and controls.** The study included 98 ALA patients, 28 amebic colitis patients, and 43 control subjects. Of the 98 ALA patients, 39 were from Bangabandhu Sheikh Mujib Medical University, Dhaka, and 59 were from Rajshahi Medical College Hospital, Rajshahi, Bangladesh. *E. histolytica* DNA was positive in liver abscess pus of all 98 ALA patients by real-time PCR assay. Most of the ALA patients were treated with antiamebic therapy before the collection of urine, saliva, and blood samples. The 28 amebic colitis patients were from the International Centre For Diarrheal Disease Research, Bangladesh (ICDDR, B) hospital, Dhaka. Forty-three unmatched control subjects from Rajshahi and Dhaka without amebic diseases were also enrolled. Informed consent was obtained from the patients and parents of the children. The Ethical Review Com-
The diagnosis of ALA was based on the following criteria: (i) a space-occupying lesion in the liver diagnosed by ultrasonography and suggestive of an hepatic abscess; (ii) clinical symptoms including fever and pain in the right hypochondrium; (iii) enlarged and/or tender liver without jaundice and/or right lower intercostal tenderness; (iv) raised right dome of the diaphragm on chest radiograph; (v) improvement after treatment with antiamebic drugs (metronidazole). All of the amebic colitis patients had diarrhea, and their stool samples had *E. histolytica* trophozoite-containing red blood cells (RBC) by microscopy and were positive by the antigen detection test (*E. histolytica* II enzyme-linked immunosorbent assay [ELISA]; TechLab). All stool samples from the amebic colitis patients were also positive by the real-time PCR assay. The stools of these control subjects were negative by the *E. histolytica* antigen detection test and real-time PCR assay.

Collection of specimens and DNA extraction. Blood, urine, saliva, and stool samples were collected from all ALA, amebic colitis, and control subjects. Liver abscess pus was collected from only ALA patients. Liver abscess pus was aspirated only for clinical purposes as judged by the clinicians caring for the patients and not for the purpose of this study. Fecal or liver abscess pus specimens (0.2 g) were washed twice with sterile phosphate-buffered saline (PBS) and centrifuged for 5 min at 14,000 rpm. DNA was isolated from these specimens using the QIAamp DNA stool minikit (Qiagen, Hilden, Germany). Five milliliters of saliva and 10 ml of urine were collected from each patient and centrifuged at 14,000 rpm for 5 min. Saliva and urine specimens were washed twice with sterile PBS and centrifuged for 5 min at 14,000 rpm, and sediments were used for extraction of DNA. DNA was extracted from 200 μl of sediment of the saliva and urine samples by using the QIAamp DNA blood minikit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. A 200-μl volume of whole blood was also used for extraction of DNA by using the same kit as per the standardization protocol of the manufacturer of this DNA extraction kit. After extraction of DNA from liver abscesses, urine, saliva, stool, and whole blood, the concentration and purity of all DNA samples were measured by spectrophotometry at 260/280 nm. DNA yields were calculated on the basis of UV absorbance and DNA concentration. The purity of the nucleic acid in the samples was considered sufficient if the ratio of the optical densities at 260 versus 280 nm was between 1.5 and 1.8.

Antigen detection. The Techlab *E. histolytica* II test (designed to specifically detect *E. histolytica*) was performed on stool specimens according to the manufacturer’s instructions. For detection of antigen in the serum, saliva, and urine samples, 100 μl of undiluted serum was added to the coated microtiter well of the kit. Liver abscess pus specimens were vortexed and centrifuged at 10,000 × g for 10 min, and 10 μl of the resulting undiluted supernatant was added to the microtiter well for antigen detection. A test was considered positive when the optical density reading of a sample at 450 nm was >0.150 (according to the manufacturer’s instructions). (9).

ELISA for detection of anti-*E. histolytica* lectin antibodies. The anti-lectin IgG ELISA was performed in 96-well microtiter plates. The plates were coated with purified *E. histolytica* Gal/GalNAc lectin. The serum samples were added to a 1:10,000 dilution of horseradish peroxidase-labeled anti-serum (Pierce Biotechnology, Rockford, Ill.). The plates were washed twice with PBS and centrifuged for 5 min at 14,000 rpm. 100 μl of 1:10,000 dilution of a 0.9% PBS–0.05% Tween 20 (final volume, 100 μl). The plates were incubated for 30 min at room temperature, washed with 0.05% Tween 20, and 100 μl of the resulting undiluted supernatant was added to the microtiter well for antigen detection. A test was considered positive if the ratio of the optical densities at 260 versus 280 nm was between 1.5 and 1.8.

Real-time PCR assay. The primers and probes for *E. histolytica* (accession no. X64142) were designed for the small subunit rDNA gene. The amplified target was 134 bp. Primers and TaqMan probes used in this study were purchased from Eurogentec (Seraing, Belgium). The *E. histolytica*-specific primers and probe set consisted of the forward primer (Eh-f), 5′-AAC AGT AGT ATG TTT TTG GGT TAG TAA AA-3′, and the reverse primer (Eh-r), 5′-CTT AGA AGT ATG TCA TTT CTC AAT TCT-3′. The TaqMan probe used in this assay was a double-labeled probe, YYT, 5′-ATT AGT ACA AAC TGG CCA ATT CAT TCA-3′ (Eclipse). A 0.4-μmol/liter concentration of each primer (Eh-f and Eh-r primers) was used in the reaction mixture of 20 μl. 1 μl of the extracted DNA was used in each reaction mixture. Amplification reactions were performed in a volume of 25 μl with Bio-Rad IQ supermix (100 mM KCl, 40 mM Tris-HCl [pH 8.4], 1.6 mM deoxynucleoside triphosphates, *i*Taq DNA polymerase [50 U/ml], 2 mM MgCl2) with an additional 3 mM MgCl2 added. Amplification consisted of 3 cycles of 3 min at 95°C, 30 s at 60°C, and 30 s at 72°C. The ramping of the machine was 3.3°C/second in every step. Amplification, detection, and data analysis were performed with the iCycler real-time detection system (Bio-Rad). Fluorescence was measured during the annealing step of each cycle. The ramping of the machine was 3.3°C/second in every step. Fluorescence was measured at 530 nm (10).

### Results

The age and sex distributions of the ALA, amebic colitis, and control subjects from whom samples were collected are given in Table 1. Eighty-eight and 60 percent of the ALA and amebic colitis patients were male, respectively. All 98 of the liver abscess pus specimens collected from the ALA patients were positive for *E. histolytica* DNA by real-time PCR assay. Positive and negative controls were included in each run of the real-time PCR assay. There were two types of positive controls, strong positive controls (10,000 trophozoites/ml) and weak positive controls (10 trophozoites/ml). The positive and negative controls always gave consistent results. The coefficient of variation of the strong positive control was 2.7%, while for the weak positive control it was 1.7% (based on threshold cycle 

**TABLE 1. Age and sex distributions of ALA, amebic colitis, and control subjects**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>ALA patients (n = 98)</th>
<th>Amebic colitis patients (n = 28)</th>
<th>Controls subjects (n = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [mean yrs (SD)]</td>
<td>42.2 (12.6)</td>
<td>24.3 (17.0)</td>
<td>36.3 (12.4)</td>
</tr>
<tr>
<td>Gender [n (%)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>86 (87.8)</td>
<td>17 (60.7)</td>
<td>39 (90.7)</td>
</tr>
<tr>
<td>Female</td>
<td>12 (12.2)</td>
<td>11 (39.3)</td>
<td>04 (09.3)</td>
</tr>
</tbody>
</table>

Gender distribution of ALA, amebic colitis, and control subjects is presented in Table 1. Out of 98 ALA patients, 80 (81.6%) were male and 18 (18.4%) were female. Out of 28 amebic colitis patients, 17 (60.7%) were male and 11 (39.3%) were female. Out of 43 control subjects, 39 (90.7%) were male, and 4 (9.3%) were female.

### Discussion

The sensitivity and specificity of the antigen detection test of TechLab. Antilectin IgG antibody in serum was detected in 96% (94/98) of ALA patients but only 46% (13/28) of amebic colitis patients. Out of 43 control subjects, 5 were also positive for antilectin IgG in their serum samples. So, the antibody-based test was 96% sensitive and 88% specific for diagnosis of ALA patients but only 46% sensitive and 88% specific for amebic colitis patients in this study.

To establish a calibration curve for this real-time PCR assay, serial dilutions of cultured trophozoites of *E. histolytica* were spiked in urine and saliva samples before extraction of DNA and then the DNA was extracted. The real-time PCR assay used in this study detects 10 trophozoites of *E. histolytica* per milliliter (Fig. 1). This is comparable to our earlier results of a similar assay using a molecular beacon probe (21). The results of the real-time PCR assay for detection of *E. histolytica* DNA in blood, urine, and saliva samples of ALA, amebic colitis, and control subjects are presented in Fig. 2. Out of 98 ALA pa-

---

**Downloaded from [http://jcm.asm.org/](http://jcm.asm.org/) on January 22, 2018 by guest**
tients, saliva samples was not collected from 3 patients. The real-time PCR assay was 49%, 77%, and 69% sensitive for detection of *E. histolytica* DNA in blood, urine, and saliva specimens, respectively, for the 95 ALA patients where both samples were tested. For the 28 amebic colitis patients the sensitivity of the real-time PCR assay for detection of *E. histolytica* DNA in blood, urine, and saliva was 36%, 61%, and 64%, respectively. All blood, urine, and saliva samples from control subjects were negative by the real-time PCR assay for *E. histolytica* DNA. When the real-time PCR assay results of the urine and saliva specimens were taken together (positive either in urine or saliva), the real-time PCR assay was 97% and 89% sensitive for detection of *E. histolytica* DNA in ALA and amebic colitis patients, respectively (Fig. 2).

A comparison of the results of the real-time PCR results from urine with saliva for the ALA and amebic colitis patients is given in Table 2. Out of 22 ALA patients whose urine samples gave negative results by the urine real-time PCR assay, 19 were positive for *E. histolytica* DNA in their saliva samples. Similarly, of 29 ALA patients whose saliva samples were negative by the real-time PCR assay, 26 were positive based on urine. Similar findings were also obtained for the amebic colitis patients (Table 2). Two of three ALA patients whose urine and saliva specimens were negative for *E. histolytica* DNA by real-time PCR assay were positive for *E. histolytica* DNA in their blood by the real-time PCR assay. Combining the real-time PCR assay results from urine and saliva gave a positive predictive value of this real-time PCR assay for diagnosis of ALA of 100% and a negative predictive value of 93%.

The semiquantitative nature of the real-time PCR may allow for the estimation of parasite load in the different clinical samples. There were no significant differences between the $C_T$ values from blood, urine, and saliva specimens of ALA and amebic colitis patients (Table 3). However, the mean $C_T$ values of the positive blood, urine, and saliva specimens of ALA patients were significantly higher than the mean $C_T$ value of the liver abscess pus specimens ($P < 0.001$). Similarly, the mean $C_T$ values of the positive blood, urine, and saliva specimens of amebic colitis patients were higher than the mean $C_T$ value of the stool specimens from the same patients ($P = 0.02$).

![FIG. 1. Calibration curve of the *E. histolytica* real-time PCR assay. Shown are the numbers of *E. histolytica* trophozoites spiked in saliva or urine samples (number of organisms per milliliter of specimen).](http://jcm.asm.org/)

![FIG. 2. Detection of *E. histolytica* DNA in blood, urine, and saliva of ALA and amebic colitis (AC) patients.](http://jcm.asm.org/)

<table>
<thead>
<tr>
<th>PCR result in saliva</th>
<th>PCR result in urine from subjects with:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ALA</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
</tr>
<tr>
<td>Negative</td>
<td>26</td>
</tr>
<tr>
<td>Positive</td>
<td>47</td>
</tr>
<tr>
<td>Total</td>
<td>73</td>
</tr>
</tbody>
</table>

* Number of patients with indicated result.
In the study we have shown that *E. histolytica* DNA can be detected either in urine or saliva in 97% (92/95) of ALA cases by real-time PCR. We have also shown that urine and saliva are more suitable specimens than blood for detection of *E. histolytica* DNA in ALA patients.

There are several reports on the use of saliva and urine for the detection of DNA for the diagnosis of infectious diseases, including amebiasis (4, 17, 18, 26). However, to our knowledge this is the first report on the use of a real-time PCR assay for detection of *E. histolytica* DNA in both urine and saliva of ALA patients. Earlier studies had attempted to detect *E. histolytica* DNA in urine or saliva in ALA patients by using conventional PCR methods, and the sensitivity was low compared to our study (14, 19).

In the present study, we have also shown that by the real-time PCR assay *E. histolytica* DNA can also be detected in blood, urine, and saliva of amebic colitis patients. And as in the case of ALA, urine and saliva were more suitable specimens than blood for detection of *E. histolytica* DNA. But the overall sensitivity for diagnosis of amebic colitis by real-time PCR on urine and saliva was far less than that of antigen detection or real-time PCR on stool samples.

In summary, detection of parasite DNA in urine and saliva provides a sensitive and noninvasive means for the diagnosis of ALA.

ACKNOWLEDGMENT

This work was supported by NIH grant R01 AI043596.

REFERENCES